Tevogen Targets Up to $14 B LT Revenue From Cancer and COVID Therapies

Tevogen Bio (NASDAQ: TVGN), a clinical-stage specialty immunotherapy biotech, has announced ambitious revenue projections for its oncology pipeline. The company forecasts $1 billion in revenue for the launch year and estimates cumulative 5-year revenue between $10-14 billion.

The company's lead candidate, TVGN 489, targets SARS-CoV-2 infection in cancer patients undergoing immunosuppressive treatments and chemotherapy. Tevogen's pipeline includes multiple candidates targeting various conditions, including cervical cancer, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis. The total eligible patient population in the US exceeds 2 million patients.

https://www.stocktitan.net/news/TVGNW/tevogen-bio-oncology-reports-top-line-revenue-forecast-of-1-billion-10riss5jt77i.html